Patient-reported outcomes and response to treatment for patients initiating ixekizumab: Findings from the Corrona Registry

Little is known regarding the effectiveness of ixekizumab, a human monoclonal antibody that selectively inhibits IL-17A, in a real-world setting. Using the Corrona Psoriasis Registry, a prospective observational cohort of patients aged 18 or older, we examined response rates to ixekizumab for patient-reported outcomes (ie, Work Productivity and Activity Impairment [WPAI], DLQI, EQ-5D, pain, itch, and fatigue) among patients with a 6-month follow-up (FU) visit after enrollment in the registry. As of May 10, 2018, 136 incident users of ixekizumab at enrollment had a 6-month FU (defined as a visit occurring in the ± 3-month window closest to 6 months postinitiation) visit available.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research